recombinant F1- LcrV fusion protein vaccine (FasCure Therapeutics)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Namerecombinant F1- LcrV fusion protein vaccine (FasCure Therapeutics)

Drug Alias NameN/A

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine +[4]

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsPlague

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesFasCure Therapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFasCure Therapeutics LLC

Active IndicationsN/A

Inactive IndicationsPlague

Other Information

ATC CodeN/A